USOR 20412 - STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-Controlled, Double-Blinded, Randomized, Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET Fusion-Positive NSCLC (LIBRETTO-432)(J2G-MC-JZJX)

Disease Types: Lung - Non-Small Cell Lung, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles